Earlier this week, the Massachusetts-based Moderna announced positive interim phase-1 or early-stage clinical trial data. Moderna's market valuation soared to $29 billion.
The Food and Drug Administration (FDA) has approved the mRNA vaccine for phase-II trials.
In this edition of the Moneycontrol's Explained series, find out if the vaccine is worth the hype.
Watch the video for more.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
